Copyright
©The Author(s) 2026.
World J Hepatol. Jan 27, 2026; 18(1): 113753
Published online Jan 27, 2026. doi: 10.4254/wjh.v18.i1.113753
Published online Jan 27, 2026. doi: 10.4254/wjh.v18.i1.113753
Figure 1 Flowchart representing patient evaluation and characterization in this retrospective cohort study.
1Standard eligibility criteria are body mass index > 40 kg/m2 or > 35 kg/m2 plus obesity-associated comorbidity. MASLD: Metabolic dysfunction-associated steatotic liver disease; BSE: Bariatric surgery eligible; BSNE: Bariatric surgery non-eligible; RYGB: Roux-en-Y gastric bypass; SG: Sleeve gastrectomy; MBSAQIP: Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program.
Figure 2 Weight and liver-related outcomes in patients with metabolic dysfunction-associated steatotic liver disease undergoing bariatric surgery vs lifestyle management/medication.
A: Comparison between total body weight loss in patients who underwent gastric bypass or sleeve gas trectomy vs non-surgical management (lifestyle/medication). P < 0.0001 for weight loss through either type of bariatric surgery compared to non-surgical management (unpaired t-test, Welch’s); B: Comparison between actual vs predicted body mass index post bariatric surgery (P = 0.12, unpaired t-test, Welch’s). The predicted body mass index was obtained using the Metabolic and Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program Bariatric Surgical Risk/Benefit Calculator; C: Change in fibrosis-4 in patients who underwent bariatric surgery vs lifestyle/medication management (P < 0.048, unpaired t-test, Welch’s); D: Change in nonalcoholic fatty liver disease fibrosis score in patients who underwent bariatric surgery vs lifestyle/medication management (P = 0.005); E: Number of patients with each fibrosis stage pre-surgery. Categories are as follows: F0-1: 2.0-8.4 kPa, F2: 8.5-9.4 kPa, F3: 9.5-13.5 kPa, F4 > 13.5 kPa; F: Change in liver stiffness from pre-surgery to post-surgery for patients undergoing bariatric surgery. TBWL: Total body weight loss; BMI: Body mass index; FIB-4: Fibrosis-4; NFS: Nonalcoholic fatty liver disease fibrosis score; RYGB: Roux-en-Y gastric bypass; SG: Sleeve gastrectomy.
- Citation: Schwartz AW, Park EY, Ilagan-Ying YC, Zimmerman ZE, Bollinger B, Ying LD, Deng YD, Duffy AJ, Morton JM, Mehal WZ, Do A, Banini BA. Impact of multidisciplinary steatotic liver disease management on bariatric surgery referral and clinical outcomes: A retrospective cohort study. World J Hepatol 2026; 18(1): 113753
- URL: https://www.wjgnet.com/1948-5182/full/v18/i1/113753.htm
- DOI: https://dx.doi.org/10.4254/wjh.v18.i1.113753
